At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6,772 enrolled
Drug / intervention
Prazaxadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Marketing Surveillance on the Long-Term Use of Prazaxa® Capsules in Patients With Nonvalvular Atrial Fibrillation
In Brief
An observational study evaluating Prazaxa for Atrial Fibrillation. Completed, enrolled 6,772 participants across 1,164 sites.
Detailed Summary
To investigate the safety and efficacy of long-term use of Prazaxa® Capsules in patients with nonvalvular atrial fibrillation for preventing the occurrence of ischemic stroke or systemic embolism (SEE).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionAug 2016
TodayJul 2026
First PostedDec 13, 2011
Enrollment StartDec 12, 2011
Primary CompletionAug 2, 2016
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.6 years ago
Interventions
Prazaxadrug
Dabigatran etexilate